/biz/ - Business & Finance

OCRX is about to pop in the next few days, Multiple analysts have moved it to a buy rating now. 10x average volume today.

Do your DD but this could be the next moon mission.

>The Company is focused on acute and chronic orphan liver diseases. Top-line results from its exploratory STOP-HE Phase 2b Study evaluating the efficacy, safety and tolerability of intravenously-administered Ornithine Phenylacetate (OCR-002) in hospitalized patients with Hepatic Encephalopathy (HE), Although not statistically significant, OCR-002 demonstrated a 17-hour reduction over placebo

The P2 study didn't quite meet expectations but was certainly a step in the right direction. After the report investors pulled out and now we're looking at a 52week low with nowhere to go but up. Most Analysts put a price target of 3-4 dollars on the stock.